Skip to content

Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in patients undergoing thoracoscopic radical resection of lung cancer : a single-center, prospective, randomized controlled clinical trial

Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in patients undergoing thoracoscopic radical resection of lung cancer : a single-center, prospective, randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083262
Enrollment
Unknown
Registered
2024-04-19
Start date
2024-04-20
Completion date
Unknown
Last updated
2024-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Penehyclidine hydrochloride group:Penehyclidine 0.25 mg is injected before anesthesia, and 0.25 mg penehyclidine is continuously infused 48 h after operation.
Control group:Normal saline 2.5 ml is injected before anesthesia and 2.5 ml normal saline is continuously infused within 48 h after operation.

Sponsors

Henan Provincial Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Age : 18 years old = age < 65 years old; 2. body mass index : 18 kg / m2 = BMI < 30 kg / m2; 3.ASA grade : I ~ III grade; 4.Surgical type : It is planned to receive thoracoscopic radical resection of lung cancer, and postoperative analgesia pump is needed after operation.

Exclusion criteria

Exclusion criteria: 1. Existence of glaucoma; 2. Allergic to penehyclidine, atropine, scopolamine or other anticholinergic drugs; 3. Acute or chronic nausea or vomiting, or preoperative gastrointestinal motility disorders; 4. History of schizophrenia, Parkinson 's disease, severe dementia or language disorder; 5.Severe liver dysfunction ( Child-Pugh C ), severe renal dysfunction; 6. ASA grade = IV; 7. Patients involved in other clinical studies.

Design outcomes

Primary

MeasureTime frame
The total incidence of PONV;

Secondary

MeasureTime frame
Partial incidence and severity of PONV;Incidence of adverse events;

Countries

China

Contacts

Public ContactZhou Junhui

Henan Provincial Chest Hospital

zhoujunhui1985@126.com+86 158 0386 5536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026